[177Lu]Lu-DOTATATE (Lutathera®) has been approved for the treatment of somatostatin receptor 2 (SSTR2) positive neuroendocrine tumours (NETs) by both EMA and FDA [8]. The gene discussed is SSTR2; the disease is neuroendocrine neoplasm.